Oleclumab vs Uliledlimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline

Oleclumab

Developed by MedImmune LLC

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03822351 · Phase 2 · completed

Participants were randomized among three treatment groups, including durvalumab monotherapy as the comparator, but the study was open-label rather than blinded; 60 participants received durvalumab plus oleclumab and 67 received durvalumab alone. The clinical primary endpoint, RECIST 1.1 objective response rate, was numerically higher with oleclumab, but statistical significance of the comparison was not reported, so the result remains unclear.

Next expected readout: January 2027 · NCT05221840 (registry estimate)

Reported efficacy

Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel Agents (ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint): Control Arm (Durvalumab Monotherapy) 23.9% (95% CI 14.3-35.9) vs Arm A (Durvalumab + Oleclumab) 35.0% (95% CI 23.1-48.4) vs Arm B (Durvalumab + Monalizumab) 40.3% (95% CI 28.1-53.6) (unclear)

Result source: NCT03822351

Uliledlimab

Developed by TJ Biopharma Co., Ltd. and partners

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT06984588 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointOleclumabUliledlimab
PFS, median21.1 vs 7.3vs Durvalumab Monotherapyn 60NCT03822351—Trial running · NCT06984588
OS, median—Trial running · NCT05221840—Trial running · NCT06984588
ORR35% vs 23.9%vs Durvalumab Monotherapywk 16 · n 60NCT03822351—Trial running · NCT06984588
Duration of response, median29.9n 21NCT03822351—Trial running · NCT06984588

PFS, median

Oleclumab
21.1 vs 7.3vs Durvalumab Monotherapyn 60NCT03822351
Uliledlimab
—Trial running · NCT06984588

OS, median

Oleclumab
—Trial running · NCT05221840
Uliledlimab
—Trial running · NCT06984588

ORR

Oleclumab
35% vs 23.9%vs Durvalumab Monotherapywk 16 · n 60NCT03822351
Uliledlimab
—Trial running · NCT06984588

Duration of response, median

Oleclumab
29.9n 21NCT03822351
Uliledlimab
—Trial running · NCT06984588
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Uliledlimab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Oleclumab: 3 of 4 rows · Uliledlimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricOleclumab
Dropout rate
51.7%Arm A (Durvalumab + Oleclumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · combination
3.7%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
14.3%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Arm A (Durvalumab + Oleclumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
—Durvalumab + Oleclumab
NCT03822351 · Phase 2 · combination
—1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
—1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—Arm A (Durvalumab + Oleclumab)a
NCT03822351 · Phase 2 · combination
show 3 more results
33.9%Durvalumab + Oleclumab
NCT03822351 · Phase 2 · combination
11.5%1500 mg
NCT03794544 · Phase 2 · registry result, not featured evidence
9.5%1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
cough 32.2%
dyspnoea 25.4%
asthenia 18.6%
NCT03822351 · Phase 2 · combination
show 2 more results
1500 mg
fatigue 23.1%
procedural pain 19.2%
asthenia 11.5%
NCT03794544 · Phase 2 · registry result, not featured evidence
1500 mg + 3000 mg
fatigue 19%
asthenia 14.3%
cough 14.3%
NCT03794544 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Oleclumab

ORR 35% (n=60) vs 23.9% (n=67) Durvalumab Monotherapy @ 16wk
responder rate · % of participants
NCT03822351 · Phase 2 · combination
Duration of Response 29.9 vs NA Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
Disease Control 80% (n=60) vs 58.2% (n=67) Durvalumab Monotherapy
responder rate · % of participants
NCT03822351 · Phase 2 · combination
PFS 21.1 vs 7.3 Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
PFS-12 63.5% (n=60) vs 37.6% (n=67) Durvalumab Monotherapy @ 52wk
responder rate · % of participants
NCT03822351 · Phase 2 · combination
Overall Survival NA vs 40.9 Durvalumab Monotherapy months
time to event · months
NCT03822351 · Phase 2 · combination
Major Pathologic 11.1% (n=27) @ 6wk1500 mg
responder rate · % of participants
No placebo or comparator arm
NCT03794544 · Phase 2 · registry result, not featured evidence
show 1 more result
19% (n=21) @ 6wk1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination
Pathologic Complete 3.7% (n=27) @ 6wk1500 mg
responder rate · % of participants
No placebo or comparator arm
NCT03794544 · Phase 2 · registry result, not featured evidence
show 1 more result
9.5% (n=21) @ 6wk1500 mg + 3000 mg
NCT03794544 · Phase 2 · registry result, not featured evidence · combination

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oleclumab's landscape · Uliledlimab's landscape